Table 5.

External validation with clinical trials 19.4.207 (P05930) [13] and 19.4.210 (P05959) [14], showing time to recovery of the train-of-four (TOF) ratio to 0.9 (TOF90) and 0.7 (TOF70), following sugammadex reversal^*

	Clinical trial	19.4.207 (P05930)					19.4.210 (P05959)
	Anaesthesia	Propofol					Propofol	Sevoflurane
End-point	Dose statistics	0.5 mg kg−1sugammadex (n = 8)	1.0 mg kg−1sugammadex (n = 7)	2.0 mg kg−1sugammadex (n = 8)	3.0 mg kg−1sugammadex (n = 3)	4.0 mg kg−1sugammadex (n = 8)	2.0 mg kg−1sugammadex (n = 21)	2.0 mg kg−1sugammadex (n = 20)
Time to TOF90 (min)	Simulated median	4.6	2.5	1.5	1.0	0.8	1.5	1.5
	Simulated 90% CI	1.5–15	0.8–7.6	0.5–5.5	0.3–4.3	0.3–3.5	0.5–5.5	0.5–8.0
	Observed median	3.7	2.2	1.7	1.5	1.1	1.7	1.7
	Observed range	2.1–4.9	1.5–3.4	0.9–2.8	1.0–3.2	0.7–1.6	0.9–3.4	1.1–4.5
Time to TOF70 (min)	Simulated median	3.5	2.0	1.3	0.8	0.8	1.1	1.3
	Simulated 90% CI	1.2–11	0.7 −6.0	0.5–4.3	0.3–3.5	0.3–2.8	0.5–4.3	0.5–6.0
	Observed median	2.4	1.4	1.3	1.0	1.0	1.2	1.3
	Observed range	1.3–2.9	1.1–2.2	0.9–1.9	0.7–2.4	0.7–1.3	0.8–2.4	0.7–1.9

^*Sugammadex was administered at reappearance of T₂ (moderate blockade reversal).